Eben Tessari Sells 14,000 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $19.57, for a total value of $273,980.00. Following the completion of the transaction, the chief operating officer now owns 81,975 shares of the company’s stock, valued at approximately $1,604,250.75. This represents a 14.59 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Eben Tessari also recently made the following trade(s):

• On Monday, January 13th, Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $18.24, for a total value of $255,360.00.

Kiniksa Pharmaceuticals Price Performance

Shares of NASDAQ KNSA opened at $19.65 on Friday. The company has a market cap of $1.42 billion, a P/E ratio of -140.35 and a beta of 0.32. Kiniksa Pharmaceuticals, Ltd. has a 1 year low of $16.56 and a 1 year high of $28.15. The firm has a 50-day simple moving average of $19.86 and a two-hundred day simple moving average of $22.94.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Evercore ISI lifted their price target on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Wedbush reiterated an “outperform” rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research report on Monday, January 13th. Finally, JPMorgan Chase & Co. lifted their price target on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Kiniksa Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $36.60.

Institutional Trading of Kiniksa Pharmaceuticals

A number of large investors have recently modified their holdings of the company. Braidwell LP boosted its holdings in shares of Kiniksa Pharmaceuticals by 40.6% in the third quarter. Braidwell LP now owns 2,894,513 shares of the company’s stock valued at $72,334,000 after purchasing an additional 836,210 shares during the period. Parkman Healthcare Partners LLC boosted its holdings in shares of Kiniksa Pharmaceuticals by 16.7% in the third quarter. Parkman Healthcare Partners LLC now owns 755,244 shares of the company’s stock valued at $18,874,000 after purchasing an additional 108,102 shares during the period. FMR LLC boosted its holdings in shares of Kiniksa Pharmaceuticals by 36,925.0% in the third quarter. FMR LLC now owns 696,810 shares of the company’s stock valued at $17,413,000 after purchasing an additional 694,928 shares during the period. Rice Hall James & Associates LLC boosted its holdings in shares of Kiniksa Pharmaceuticals by 8.2% in the third quarter. Rice Hall James & Associates LLC now owns 649,630 shares of the company’s stock valued at $16,234,000 after purchasing an additional 49,000 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Kiniksa Pharmaceuticals by 2.0% in the fourth quarter. Geode Capital Management LLC now owns 492,630 shares of the company’s stock valued at $9,744,000 after purchasing an additional 9,654 shares during the period. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.